Exploring the integration of patient-reported outcome measures in clinical practice: A cross-sectional survey of EORTC healthcare professionals

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-03-01 DOI:10.1016/j.ejca.2025.115333

Jens Lehmann , Tatiana Dragan , Elke Rammant , Kelly M. de Ligt , Julia Lai-Kwon , Emma Lidington , Renée Bultijnck , Daniel Dejaco , Katherine J. Taylor , Tihana Gašpert , Elena Colombo , Ainhoa Madariaga , Mariana Brandão , Jan P. Nicolay , Ioannis Zerdes , Francesca Bosisio , Dora Correia , Alessia Pellerino , Gloria Marquina , Mário Fontes-Sousa , Petr Szturz

{"title":"Exploring the integration of patient-reported outcome measures in clinical practice: A cross-sectional survey of EORTC healthcare professionals","authors":"Jens Lehmann , Tatiana Dragan , Elke Rammant , Kelly M. de Ligt , Julia Lai-Kwon , Emma Lidington , Renée Bultijnck , Daniel Dejaco , Katherine J. Taylor , Tihana Gašpert , Elena Colombo , Ainhoa Madariaga , Mariana Brandão , Jan P. Nicolay , Ioannis Zerdes , Francesca Bosisio , Dora Correia , Alessia Pellerino , Gloria Marquina , Mário Fontes-Sousa , Petr Szturz","doi":"10.1016/j.ejca.2025.115333","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used in practice.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional survey (November 2023-April 2024) among healthcare professionals (HCPs) in the European Organisation for Research and Treatment of Cancer (EORTC). Descriptive statistics and chi-square tests assessed PROM use patterns, regional differences, and barriers. Binary regression models compared barriers between PROM users and non-users.</div></div><div><h3>Results</h3><div>Of the 3733 EORTC members contacted, 784 responded (21 % response rate), predominantly physicians. Among the 784 HCPs (50 % women), 338 (43 %) did not use PROMs, 214 (27 %) were occasional users, and 232 (30 %) used PROMs regularly. PROM use was significantly higher in Western Europe than in Central/Eastern Europe. PROMs were primarily used for monitoring health status and enhancing communication. PROM use was highest among HCPs treating bone, soft tissue, genito-urinary, and gynecological cancers, and lowest in lung cancer. Key barriers to PROM use included lack of time (reported by 70 % of respondents) and insufficient support on how to use PROMs (73 %). Compared to non-users, PROM users more frequently identified patient-level barriers, such as accessibility concerns, as relevant (Odds Ratio 3.5, 95 % Confidence Interval 2.4–5.3).</div></div><div><h3>Conclusions</h3><div>PROM use varies by cancer type, setting, and region. Addressing time constraints, providing support, and overcoming patient barriers are key to broader integration. Ensuring equitable access to PROM tools across regions and settings is vital for promoting equity in cancer care.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"220 ","pages":"Article 115333"},"PeriodicalIF":7.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925001145","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used in practice.

Methods

We conducted a cross-sectional survey (November 2023-April 2024) among healthcare professionals (HCPs) in the European Organisation for Research and Treatment of Cancer (EORTC). Descriptive statistics and chi-square tests assessed PROM use patterns, regional differences, and barriers. Binary regression models compared barriers between PROM users and non-users.

Results

Of the 3733 EORTC members contacted, 784 responded (21 % response rate), predominantly physicians. Among the 784 HCPs (50 % women), 338 (43 %) did not use PROMs, 214 (27 %) were occasional users, and 232 (30 %) used PROMs regularly. PROM use was significantly higher in Western Europe than in Central/Eastern Europe. PROMs were primarily used for monitoring health status and enhancing communication. PROM use was highest among HCPs treating bone, soft tissue, genito-urinary, and gynecological cancers, and lowest in lung cancer. Key barriers to PROM use included lack of time (reported by 70 % of respondents) and insufficient support on how to use PROMs (73 %). Compared to non-users, PROM users more frequently identified patient-level barriers, such as accessibility concerns, as relevant (Odds Ratio 3.5, 95 % Confidence Interval 2.4–5.3).

Conclusions

PROM use varies by cancer type, setting, and region. Addressing time constraints, providing support, and overcoming patient barriers are key to broader integration. Ensuring equitable access to PROM tools across regions and settings is vital for promoting equity in cancer care.

查看原文本刊更多论文

探索临床实践中患者报告的结果测量的整合：EORTC医疗保健专业人员的横断面调查

背景：在常规护理中使用患者报告结果测量（PROMs）对癌症患者有显著的潜在益处，但目前尚不清楚它们在实践中的应用有多广泛。方法我们于2023年11月至2024年4月对欧洲癌症研究与治疗组织（EORTC）的卫生保健专业人员（HCPs）进行了横断面调查。描述性统计和卡方检验评估了PROM的使用模式、区域差异和障碍。二元回归模型比较了PROM用户和非用户之间的障碍。结果在联系的3733名EORTC成员中，有784名回复（21. %回复率），主要是医生。在784名HCPs中（50 %为女性），338名（43 %）不使用prom， 214名（27 %）偶尔使用，232名（30 %）经常使用prom。西欧的PROM使用率明显高于中欧/东欧。prom主要用于监测健康状况和加强通信。在治疗骨癌、软组织癌、泌尿生殖系统癌和妇科癌的HCPs中，PROM的使用率最高，而在肺癌中使用率最低。使用PROM的主要障碍包括缺乏时间（70% %的受访者报告）和对如何使用PROM的支持不足（73% %）。与非使用者相比，PROM使用者更频繁地识别出患者层面的障碍，例如可访问性问题（优势比3.5,95 %置信区间2.4-5.3）。结论prom的使用因肿瘤类型、环境和地区而异。解决时间限制、提供支持和克服患者障碍是实现更广泛整合的关键。确保在不同区域和环境中公平获得PROM工具对于促进癌症治疗的公平性至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.